Zoetis Sees Softer Pet Health Demand, But Adapting Commercial Strategy to Navigate Headwinds
Zoetis beat second-quarter earnings estimates but missed on revenue, cut 2026 guidance and cited weaker pet health demand and pricing pressure.
Zoetis made more money than expected per share, but sold less total stuff than hoped because fewer people are buying pet medicines right now. The company is changing how it does business to handle this, so watch whether their new plan actually helps them sell more in the coming months.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.